You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 3 | BMC Infectious Diseases

Figure 3

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

Figure 3

Solicited symptoms following (a) primary vaccination (overall/dose; primary TVC) and (b) booster dose (booster TVC). TVC = total vaccinated cohort. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase. ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase. Error bars represent 95% confidence intervals. Solicited symptoms are recorded during 4-days post-vaccination.

Back to article page